Clinical Research by Disease

The Department of Radiation Oncology enrolls as many as 80 new patients each year in clinical trials. Faculty members hold leadership positions in the Radiation Therapy Oncology Group (RTOG), which develops and oversees all national radiation oncology trials funded by the National Cancer Institute.

See current clinical trial information below or contact the Clinical Research office at 214-648-1892


Randomized phase II trial of hypofractionated dose-escalated photon IMRT or proton beam therapy versus conventional photon irradiation with concomitant and adjuvant temozolomide in patients with newly diagnosed glioblastoma

Interstitial radioactive iodine implants for the treatment of pan-invasive pituitary macroadenomas
Phase II trial of hippocampal-avoiding whole brain irradiation with simultaneous integrated boost for treatment of brain metastases


Randomized, double-blind, vehicle-controlled pilot study of the efficacy and safety of HylaCareTM in the treatment of acute skin changes in patients undergoing external beam radiotherapy for tumors of the breast

A phase I study of CyberKnife® partial breast irradiation (PBI) for early stage breast cancer


Phosphatidylserine-targeting antibody bavituximab in combination with capecitabine and radiation therapy for the treatment of stage II and III rectal adenocarcinoma


Phase II study of stereotactic ablative radiotherapy (SABR) for low risk prostate cancer with injectable rectal spacer

Androgen deprivation therapy and high dose radiotherapy with or without whole-pelvic radiotherapy in unfavorable intermediate or favorable high risk prostate cancer: a phase III randomized trial
RTOG 924

A phase II trial of stereotactic ablative body radiation therapy (SABR) for patients with primary renal cancer (RCC)

A phase II trial of high dose IL-2 and stereotactic ablative body radiation (SABR) for patients with metastatic clear cell renal cell cancer (mRCC)

Phase II trial of sipuleucel-T and stereotactic ablative body radiation (SABR) for patients with metastatic castrate-resistant prostate cancer (mCRPC)

A phase III prospective randomized trial of dose-escalated radiotherapy with or without short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer
RTOG 0815

A phase III trial of short term androgen deprivation with pelvic lymph node or prostate bed only radiotherapy (SPPORT) in prostate cancer patients with a rising PSA after radical prostatectomy
RTOG 0534


Phase II study for image-guided hypofractionated radiation boost therapy for definitive treatment of locally advanced cervical cancer

A randomized phase III study of standard vs. IMRT pelvic radiation for postoperative treatment of endometrial and cervical cancer (TIME-C)
RTOG 1203 

Head and Neck

A phase I trial of stereotactic HYpofractionateD RadioAblative (HYDRA) treatment of advanced laryngeal cancer

A phase I study of reduced volume hypofractionated, PET-directed intensity modulated radiotherapy concurrent with weekly cisplatin chemotherapy for T1/NO-2 squamous cell carcinoma of the head and neck

Randomized phase II and phase III studies of individualized treatment for nasopharyngeal carcinoma based on biomarker Epstein Barr virus (EBV) deoxyribonucleic acid (DNA)

Tryhard: a phase II, randomized, double blind, placebo-controlled study of lapatinib (Tykerb) for non-HPV locally advanced head and neck cancer with concurrent radiation
RTOG 3501

A phase 1 CyberKnife accelerated hemilarynx stereotactic radiotherapy study for early-stage glottic larynx cancer

Randomized phase II/III trial of surgery and postoperative radiation delivered with concurrent cisplatin versus docetaxel versus docetaxel and cetuximab for high-risk squamous cell cancer of the head and neck
RTOG 1216

Phase III study of postoperative radiation therapy (IMRT) /- Cetuximab for locally-advanced resected head and neck cancer
RTOG 0920

Lung (Thoracic)

Small Cell Lung Cancer

Phase III comparison of thoracic radiotherapy regimes with Cisplatin and Etoposide in limited small cell lung cancer
CALGB 30610/RTOG 0538

Non-Small Cell Lung Cancer

Randomized Phase II study of preoperative chemoradiotherapy +/- Panitumumab followed by consolidation chemotherapy in potentially operable locally advanced (Stage IIIA, N2+) non-small cell lung cancer
RTOG 839

Maintenance chemotherapy versus consolidative stereotactic body radiation therapy (SBRT) plus maintenance chemotherapy for stage IV non-small cell lung cancer (NSCLC): a randomized phase II trial

A randomized phase II study of individualized combined modality therapy for stage III non-small cell lung cancer (NSCLC)
RTOG 1306

A randomized phase I/II study of nab-paclitaxel, or paclitaxel, plus carboplatin with concurrent radiation therapy followed by consolidation in patients with favorable prognosis inoperable stage IIIA/B NSCLC

Phase III randomized study of standard versus accelerated hypofractionated image-guided radiation therapy (IGRT) in patients with stage II-III non-small cell lung cancer and poor performance status


Phase II study of stereotactic body radiation therapy and vertebroplasty for localized spine metastasis

Phase II/III study of Image-guided radiosurgery/SBRT for localized spine metastasis
RTOG 0631

For more information, please contact Clinical Research Manager Jean Wu at 214-633-1753 or